Abstract
A timed-release derivative of mitomycin C (MMC), agarose bead conjugate (MMC-AB), was synthesized using cyanogen bromide method. MMC was released successively for considerably longer period from MMC-AB in vitro and in vivo after intraperitoneal injection to mice. MMC-AB exhibited almost identical inhibitory effect against growth of Ehrlich ascites carcinoma (EAC) cells to free MMC and less toxicity to ddY mouse than free MMC. Calculated therapeutic index (LD10/ED90) of MMC-AB was two times greater than that of free MMC, suggesting its advantage in cancer chemotherapy. On the life span of EAC bearing ddY mouse, MMC-AB showed almost similar efficiency with that of free MMC but less activity was exhibited against BDF1 mouse transplanted L1210 leukemia.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
